27 Sep Prostate Ca Survival: ZD4054

In an article out of Reuters from the 25th of Spetember, it was reported that AstraZeneca gave a report at the Eastern Society for Therapeutic Radiation Oncology                                (Barcelona, Spain) that there drug ZD4054 has shown to extend the lives of patients with advanced prostate cancer by as much as 7 months. In a statement released in July of this year by AstraZeneca stated that ZD4054 demonstrated overall survival benefits and was going to be moved to...